Infinity Pharmaceuticals, Inc.
INFI
INFI was delisted on the 13th of September, 2023.
74 hedge funds and large institutions have $53.7M invested in Infinity Pharmaceuticals, Inc. in 2017 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 15 increasing their positions, 25 reducing their positions, and 22 closing their positions.
265% more call options, than puts
Call options by funds: $259K | Put options by funds: $71K
8% less funds holding
Funds holding: 80 → 74 (-6)
27% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 22
40% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 25
57% less capital invested
Capital invested by funds: $125M → $53.7M (-$70.9M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
+$1.43M |
| 2 |
Millennium Management
New York
|
+$1.03M |
| 3 |
Legal & General Group
London,
United Kingdom
|
+$647K |
| 4 |
D.E. Shaw & Co
New York
|
+$442K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$429K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$6.36M |
| 2 |
BlackRock
New York
|
-$4.03M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.44M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$758K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$736K |
INFI Hedge Fund Activity: Q2 2017 in Review
74 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q2 2017, worth a combined $53.7M — down 57% from $125M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of INFI and 16 opened new positions — a net loss of 6 holders — while 25 trimmed existing stakes and 15 added.
The largest buyer was Foresite Capital Management III, opening a new position worth an estimated $1.43M. The largest seller was Deerfield Management, exiting entirely with an estimated $6.36M sold.
- 74 institutional investors held Infinity Pharmaceuticals, Inc. (INFI) as of Q2 2017, down from 80 in Q1 2017.
- Funds reported $53.7M of Infinity Pharmaceuticals, Inc. stock for Q2 2017, down 57% quarter-over-quarter.
- 16 funds opened new Infinity Pharmaceuticals, Inc. positions in Q2 2017 and 22 closed out, a net change of -6 holders.
- The largest Infinity Pharmaceuticals, Inc. buyer in Q2 2017 was Foresite Capital Management III, an estimated $1.43M added.
- The largest Infinity Pharmaceuticals, Inc. seller in Q2 2017 was Deerfield Management, an estimated $6.36M sold.
Based on aggregated 13F filings for Q2 2017.